Release Date: March 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide details on the LOTIS-7 update expected in Q2? A: We haven't disclosed the specific forum or exact timing within Q2 for sharing the LOTIS-7 data. However, we are on track to enroll 40 patients in the dose expansion in the second quarter. We will share safety and efficacy data on a portion of those patients in Q2 and data on all 40 patients in the second half of the year. - Ameet Mallik, CEO
Q: How do you view the impact of Pfizer's ADCETRIS approval on ZYNLONTA's market position? A: The approval of ADCETRIS plus R-squared in the third-line setting is expected to have limited impact. Physicians have multiple options, and based on our market research, any use of ADCETRIS is likely to replace older regimens like R-squared or R-based chemo in the third-line plus DLBCL setting. - Ameet Mallik, CEO
Q: What is the market opportunity for ZYNLONTA in indolent lymphomas? A: Based on compelling data presented in marginal zone lymphoma and follicular lymphoma, we believe the peak opportunity for ZYNLONTA in indolent lymphomas will be in the $100 million to $200 million range, assuming regulatory approval and compendia listing. - Ameet Mallik, CEO
Q: How does the LOTIS-5 trial impact your strategy for LOTIS-7? A: LOTIS-5 and LOTIS-7 are complementary approaches addressing different patient needs. LOTIS-5 offers a non-systemic chemo combination with favorable safety and convenience, while LOTIS-7 aims to be the preferred bispecific combination in second-line plus DLBCL. Both approaches allow us to cater to patients who can't access or are not suitable for CAR-T or bispecific therapies. - Ameet Mallik, CEO
Q: What are the benchmarks for LOTIS-5 to be considered competitive in terms of efficacy and safety? A: For LOTIS-5, a complete response rate north of 40% would be differentiated. The study is powered to show a two-month difference in PFS compared to R-GemOx, which typically has a PFS of three to four months. We are encouraged by the safety run-in data showing an overall response rate of 80% and a complete response rate of 50%. - Ameet Mallik, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.